> 95% as determined by Tris-Bis PAGE,> 95% as determined by HPLC
过滤
0.22 μm filtered
内毒素水平
Less than 1EU per μg by the LAL method.
Biological Activity Comment
Immobilized Human VEGF165 at 1μg/ml (100μl/well) on the plate. Dose response curve for Human VEGFR2, mFc Tag with the EC50 of 74.2ng/ml determined by ELISA. See testing image for detail.
宿主: 人
宿主: 大肠杆菌(E. Coli)
Recombinant
> 95 % by SDS-PAGE
Active
限制
仅限研究用
状态
Lyophilized
溶解方式
Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/mL is recommended (usually we use 1 mg/mL solution for lyophilization). Dissolve the lyophilized protein in distilled water.
缓冲液
Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 5 % trehalose is added as protectant before lyophilization.
储存条件
4 °C,-80 °C
储存方法
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
有效期
12 months
抗原
VEGF 165
别名
VEGF165
背景
VEGF, VEGFA, MVCD1, VAS, VEGFMGC70609, VPF, RP1-261G23.1, MGC70609,Human papillomavirus (HPV) infection is an established risk factor for cervical carcinogenesis. VEGF165 was significantly higher, whereas VEGFC and VEGFD were significantly lower in malignant cervical carcinoma tissues as compared to normal cervix tissues. Expression levels of VEGF121 and VEGFC were significantly associated with type of tumor growth while VEGF165 was significantly associated with lymph node metastasis.
分子量
19.2 kDa. Due to glycosylation, the protein migrates to 20-30 kDa based on Tris-Bis PAGE result.